- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
SUPPORT PHILSTAR
About Us |
Contact Us |
Advertise |
Privacy Policy |
Member Agreement |
Copyright Notice
Copyright © 2024. Philstar Global Corp. All Rights Reserved
X
+ Follow SANOFI-SYNTHELABO AND CEPHALON Tag
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 147972 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-22 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [1] => Array ( [ArticleID] => 147162 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-15 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [2] => Array ( [ArticleID] => 146353 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-08 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [3] => Array ( [ArticleID] => 145603 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [4] => Array ( [ArticleID] => 145286 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2001-12-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) ) )
SANOFI-SYNTHELABO AND CEPHALON
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 147972 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-22 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [1] => Array ( [ArticleID] => 147162 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-15 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [2] => Array ( [ArticleID] => 146353 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-08 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [3] => Array ( [ArticleID] => 145603 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [4] => Array ( [ArticleID] => 145286 [Title] => Sanofi-Synthelabo and Cephalon ink agreement [Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2001-12-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) ) )
abtest
January 22, 2002 - 12:00am
January 15, 2002 - 12:00am
January 8, 2002 - 12:00am
January 1, 2002 - 12:00am
December 29, 2001 - 12:00am
Recommended
The Insurance Commission has placed health maintenance organization Stotsenberg Healthcare Systems Inc.under conservatorship amid its inability to address requirements from the government.
4 days ago
Lotto Sep 22, 2024
EZ2 - 31 7
SUERTRES - 7 5 3
6/49 Lotto - 6 35 10 18 47 45
P67,771,206.00
6/58 Ultra Lotto - 24 56 8 52 4 36
P189,422,782.00
Forex
February 12, 2018
- 12:00 am
- 12:00 am
1$ : P51.66